Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;113(2):208-217.
doi: 10.1111/ejh.14216. Epub 2024 Apr 24.

Plasma microbial cell-free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia

Catherine Aftandilian  1 , Xue Rachel Bito  2 , David Berman  3 , Amy Zhang  4 , Radha Duttagupta  5 , Kara L Davis  1
Affiliations

Plasma microbial cell-free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia

Catherine Aftandilian et al. Eur J Haematol. 2024 Aug.

Abstract

Chimeric antigen receptor (CAR) T cell therapy is a promising treatment for pediatric patients with relapsed or refractory B cell acute lymphoblastic leukemia (R/R B ALL). Cytokine release syndrome (CRS) is a common toxicity after CAR T cell therapy and fever is often the first symptom. Differentiating CRS from infection after CAR T cell therapy can be challenging. Plasma microbial cell free DNA (mcfDNA) is a novel diagnostic tool which allows for qualitative and quantitative assessment of over 1000 organisms. This pilot study sought to characterize mcfDNA results in pediatric patients with R/R B ALL in the first 2 months after CAR T cell therapy.

Keywords: CAR T cell therapy; leukemia; microbial cell free DNA.

PubMed Disclaimer

References

REFERENCES

    1. Gardner RA, Finney O, Annesley C, et al. Intent‐to‐treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322‐3331.
    1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and Young adults with B‐cell lymphoblastic leukemia. N Engl J Med. 2018;378:439‐448.
    1. Budde LE, Zaia JA. CD19 CAR‐T therapy and sepsis: dancing with the devil. Blood. 2018;131:7‐8.
    1. Vora SB, Waghmare A, Englund JA, Qu P, Gardner RA, Hill JA. Infectious complications following CD19 chimeric antigen receptor T‐cell therapy for children, adolescents, and Young adults. Open forum. Infect Dis. 2020;7:ofaa121.
    1. Moskop AVM, Prabhu S, Phillips CL, et al. Immune reconstitution and infections in the real‐world use of Tisagenlecleucel in pediatric and Young adult ALL. Transplant Cell Therapy Meet. 2021;27:S335‐S336.

MeSH terms

Substances

LinkOut - more resources